Our News on Newswise

MD Anderson's fifth annual Boot Walk to End Cancer® goes virtual Nov. 7

The University of Texas MD Anderson Cancer Center will host the fifth annual Boot Walk to End Cancer® virtually on Saturday, Nov. 7. The virtual walk will take place online and in neighborhoods across the country in an effort to keep participants,...
20-Oct-2020 10:25 AM EDT Add to Favorites

Newswise: 20-MDACC-0011FocusFundLogoP2.png

Focus Fund and MD Anderson launch investment fund to support promising investigational cancer therapies in early-stage clinical trials

The Focus Fund GP, LLC, in partnership with The University of Texas MD Anderson Cancer Center, has launched Cancer Focus Fund, LP, an oncology-focused investment fund designed to support the advancement of compelling investigational cancer therapies...
20-Oct-2020 8:25 AM EDT Add to Favorites

MD Anderson and Allogene Therapeutics announce strategic collaboration to accelerate advancement of allogeneic CAR T therapy (AlloCAR T)

MD Anderson and Allogene today announced a strategic five-year collaboration for preclinical and clinical investigation of allogeneic CAR T cell therapies.
15-Oct-2020 10:45 AM EDT Add to Favorites

Newswise: 179616_Gao_J.jpg

Dual checkpoint blockade promising as pre-surgical approach for certain patients with localized bladder cancer

Phase I trial finds neoadjuvant combination checkpoint inhibitors (anti-CTLA-4 plus anti-PD-1) was well tolerated and showed early signs of activity in certain patients with bladder cancer. These patients cannot be treated with chemotherapy and have...
8-Oct-2020 1:50 PM EDT Add to Favorites

Newswise: 169902_Akdemir_K.jpg

Study finds cancer mutations accumulate in distinct regions based on structure of genome and mutational causes

A study finds that cancer mutations occur in distinct patterns based on the 3D structure of the genome and the underlying cause of the mutation. This helps us to understand cancer better and may lead to new treatment approaches.
5-Oct-2020 11:20 AM EDT Add to Favorites

Study identifies characteristics of infused CAR T cells associated with efficacy and toxicity in patients with large B-cell lymphoma

Researchers at The University of Texas MD Anderson Cancer Center have identified molecular and cellular characteristics of anti-CD19 CAR T cell infusion products associated with how patients with large B-cell lymphoma (LBCL) respond to treatment and...
5-Oct-2020 11:00 AM EDT Add to Favorites

Newswise: Liang.jpg

Next-gen bioinformatics tool enables big data analysis without programming expertise

A new data analysis tool developed by researchers at The University of Texas MD Anderson Cancer Center incorporates a user-friendly, natural-language interface to allow biomedical researchers without specialized expertise in bioinformatics or...
24-Sep-2020 11:40 AM EDT Add to Favorites

MD Anderson and Taiho Pharmaceutical announce collaboration to accelerate development of novel therapies for brain metastasis and other unmet medical needs

The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical Co., Ltd., today announced a three-year strategic collaboration to accelerate the development of treatments for significant unmet medical needs in oncology, including...
24-Sep-2020 11:10 AM EDT Add to Favorites


See All News

Our Experts on Newswise

Newswise: BenjaminSmith.jpg

Mastectomy Plus Reconstruction Has Highest Rate of Complication, Complication-Related Costs of Guideline-Concordant Therapies for Early Breast Cancer

In a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age.
27-Sep-2016 3:05 PM EDT

Newswise: Liang_H_Bronto.jpg

Can Gender Play a Role in Determining Cancer Treatment Choices?

It is well known that men and women differ in terms of cancer susceptibility, survival and mortality, but exactly why this occurs at a molecular level has been poorly understood.
9-May-2016 12:00 PM EDT

Newswise: ZhiminLu.jpg

MD Anderson Study Reveals New Insight Into Tumor Progression

Scientists know that activation of growth factor receptors like epidermal growth factor receptors (EGFR) promote tumor progression in many types of cancer.
17-Aug-2015 11:00 AM EDT

Newswise: Lee_M.jpg

Poor Survival Among Colorectal Cancer Patients Tied to Biomarker CSN6

A protein called CSN6 has been found to be correlated with poor survival among patients with colorectal cancer, according to a study at The University of Texas MD Anderson Cancer Center.
10-Aug-2015 12:00 PM EDT

Newswise: 204929_Chhatwal_Jjpg.jpg

MD Anderson Study Predicts New Hepatitis C Drugs Will Place a Dramatic Financial Strain on the Health Care System

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country’s health care system. The prediction comes from a cost-effectiveness analysis led by...
16-Mar-2015 6:00 PM EDT

MD Anderson Joins CATCH Global Foundation to Boost Child Health, Prevent Cancer in Later Years

Cancer prevention experts at The University of Texas MD Anderson Cancer Center have allied with the CATCH Global Foundation, whose comprehensive child health program reaches children and their families in more than 10,000 educational settings...
18-Feb-2015 10:00 AM EST

MD Anderson Energy Balance Expert Available for Obesity, Cancer Stories

30-Oct-2013 8:10 PM EDT

MD Anderson Obesity and Cancer Expert Researches Food Addiction

30-Oct-2013 8:00 PM EDT

See All Experts

Our YouTube Videos

About

About section not configured. Is this your member page? Login to edit, or contact member@newswise.com to configure this module.

Contacts

Clayton Boldt
Program Manager, Public Relations

crboldt@mdanderson.org

713-792-9518

Katrina Burton
Senior Communications Specialist

kburton@mdanderson.org

713-792-8034

Kelly Calagna

kccalgna@mdanderson.org

Meagan Raeke

meraeke@mdanderson.org

Allison Schaffer
Senior Communications Specialist

ASchaffer@mdanderson.org

713-745-1357

Twitter

close
0.72516